Why the Luster of Gilead's Strong Q3 Results Isn't as Bright as It Seems

Why the Luster of Gilead's Strong Q3 Results Isn't as Bright as It Seems

Sales soared for the biotech's new COVID-19 drug, but Gilead faces some challenges in other areas.